聂建华,李 顺,张书源.CDK4/6抑制剂治疗消化道肿瘤的研究进展[J].肿瘤学杂志,2021,27(10):805-812.
CDK4/6抑制剂治疗消化道肿瘤的研究进展
Progress on CDK4/6 Inhibitors for Gastrointestinal Cancer
投稿时间:2020-10-09  
DOI:10.11735/j.issn.1671-170X.2021.10.B003
中文关键词:  CDK4/6抑制剂  消化道肿瘤  靶向治疗  联合治疗
英文关键词:CDK4/6 inhibitors  gastrointestinal cancer  target therapy  combination therapy
基金项目:国家自然科学基金(81872435,81672930)
作者单位
聂建华 哈尔滨医科大学附属肿瘤医院 
李 顺 哈尔滨医科大学附属肿瘤医院 
张书源 哈尔滨医科大学附属肿瘤医院 
摘要点击次数: 911
全文下载次数: 200
中文摘要:
      摘 要:CDK4/6抑制剂(CDK4/6 inhibitors,CDK4/6i)通过调控Rb/E2F通路,诱导细胞周期停滞,抑制细胞增殖,发挥抗肿瘤作用,被FDA批准用于乳腺癌的治疗,并在多个瘤种中被广泛研究。在消化道肿瘤相关研究中,CDK4/6i表现出较好的抗肿瘤活性,并可与化疗、靶向治疗、免疫治疗和放疗等产生良好的协同效果。全文现就CDK4/6i近年在消化道肿瘤的研究进展作一综述。
英文摘要:
      Abstract: CDK4/6 inhibitors(CDK4/6i) can arrest the cell cycle and inhibit cell proliferation through regulating the Rb/E2F pathway, which have been approved by FDA for treatment of breast cancer and also widely studied in other tumor types. In gastrointestinal cancer, CDK4/6i has shown excellent antitumor activity with optimal synergistic effect with chemotherapy, target therapy, immunotherapy and radiotherapy. This article reviews the progress on CDK4/6i for treatment of gastrointestinal cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器